profit from every $100 of sales.
$0$100
PharmaCyte Biotech
$6.68+1,561.69% today
+745.5% in 1 year
1-year low $0.301-year high $6.68
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $0.12 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What PharmaCyte Biotech sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with $30.7 million of profit last year.
SalesProfit
PharmaCyte Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| PharmaCyte Biotech | 0.1× · No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads PharmaCyte Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -4 | -6 | -7 | -4 | |
| -4 | -6 | -7 | -4 | |
| -4 | -4 | 0 | 31 | |
| -0.27 | -0.22 | -1.80 | 3.19 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 91 | 73 | 60 | 55 |
| Cash | 85 | 68 | 50 | 15 |
| Total debt | – | – | – | – |
| Total liabilities | 1 | 1 | 20 | 3 |
| 90 | 73 | 40 | 52 | |
| 16 | 19 | 10 | 7 | |
| -3.7% | -7.0% | -13.0% | -6.7% | |
| -4.7% | -5.9% | 0.8% | 59.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -4 | -2 | -3 | |
| – | – | – | – | |
| -4 | -4 | -2 | -3 | |
| Dividends paid | – | – | – | – |
| 0 | 14 | 44 | 25 | |
| 0 | 1 | 1 | 0 |
Valuation
- 0.1×
- –
- –
- 0.2×
- –
- –
- 1.2×
- -78.9%
- 812.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -9.9%
- -0.7%
- -7.7%
- -5.9%
- -9.9%
- –
Growth
- –
- –
- −38.4%
- –
- +50.0%
Financial health
- -1.6×
- 0.00
- 0.0%
- –
- 12.33
- 12.33
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 23%of 952
Bottom 20%of 884
Top 1%of 601
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 17, 2026 | 0.13 | -0.06 | +316.7% |
| Dec 18, 2025 | -0.32 | – | – |
| Sep 15, 2025 | -0.09 | – | – |
| Aug 11, 2025 | 1.73 | – | – |
| Mar 17, 2025 | -0.10 | – | – |
| Dec 13, 2024 | -0.29 | – | – |
| Sep 16, 2024 | 0.14 | – | – |
| Aug 13, 2024 | -0.85 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
84Pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
27No pass
Terry Smith
20No pass
Questions about PharmaCyte Biotech
Is PharmaCyte Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PharmaCyte Biotech AI analysis
What does PharmaCyte Biotech do?
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. It is in Biotechnology.
Does PharmaCyte Biotech pay a dividend?
No. PharmaCyte Biotech does not pay a dividend at the moment; in 2025 it returned $25.0 million to shareholders by buying back its own shares.
Is PharmaCyte Biotech stock halal?
No. PharmaCyte Biotech does not pass our halal screen: its cash and confirmed interest-bearing investments are 402% of its market value, at or above the 33% limit. How we check
How has PharmaCyte Biotech stock done over the past year?
Up 745.5% over the past twelve months, to $6.68. It traded between $0.30 and $6.68, close to its high.
Who are PharmaCyte Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with PharmaCyte Biotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.